Select region:

Clinical trials located in

Paris

Paris city is located in France. Currently, 20 clinical trials are being conducted in this city.

Paris, France’s capital, is a major European city and a global center for art, fashion, gastronomy, and culture. Its 19th-century cityscape is crisscrossed by wide boulevards and the River Seine. Beyond such landmarks as the Eiffel Tower and the 12th-century, Gothic Notre-Dame cathedral, the city is known for its cafe culture and designer boutiques along the Rue du Faubourg Saint-Honoré. Paris is also renowned for its museums and cultural institutions, including the Louvre, which houses thousands of works of art, making it the world’s largest art museum. The city’s literary history is vibrant, having been home to countless writers and intellectuals. Paris’ influence in politics, education, entertainment, media, fashion, science, and the arts all contribute to its status as one of the world’s major cities.

  • CT-EU-00112556

    Study on Mexiletine effectiveness in children and adolescents with myotonic disorders

    It is a study focusing on children and adolescents affected by myotonic disorders. The purpose of this study is to examine the impact of a medication named mexiletine on individuals aged between 6 to less than 18 years. The objectives include understanding the medication’s mechanisms within the body, assessing its safety, and determining its efficacy in managing myotonic disorders.

    The study is structured into two segments, differentiated by age categories. Initially, enrollment will be open for adolescents aged 12 to less than 18 years. Should this initial phase indicate that the medication is safe, the enrollment will extend to younger children, aged 6 to less than 12 years. The duration of participation for each subject in the study is approximately 8 weeks, encompassing a 4-week phase for medication dose adjustment, followed by another 4 weeks to maintain the most well-tolerated dose.

    Ensuring safety is of paramount concern, necessitating rigorous monitoring of all participants for any adverse events or significant health changes. This includes comprehensive heart health evaluations through ECG assessments. The effectiveness of Mexiletine in alleviating symptoms associated with myotonic disorders, such as muscle stiffness and challenges in muscle relaxation post-use, will be assessed using specific tests.

    Upon the study’s conclusion, participants are offered the option to enter a follow-up study to persist in observing Mexiletine’s effects.

    France
  • Evaluating the Safety and Effectiveness of DYNE-101 for Myotonic Dystrophy Type 1 Patients

    This clinical trial is focused on evaluating a new treatment called DYNE-101 for individuals with Myotonic Dystrophy Type 1 (DM1). The main goal is to see how safe and tolerable this treatment is when given through an intravenous (IV) infusion, which means directly into the vein. The study is designed to carefully monitor how participants respond to multiple doses of DYNE-101 over time.

    The trial is structured into four main phases. It starts with a Screening Period that lasts up to 8 weeks to determine eligibility. Following this, there is a multiple-ascending dose (MAD) Placebo-Controlled Period that goes on for 24 weeks, where the safety and effectiveness of different doses of DYNE-101 are compared against a placebo (a treatment with no active drug). This is to ensure that any changes in participants’ health can be accurately attributed to the treatment. After this phase, there is a Treatment Period of another 24 weeks, where all participants receive DYNE-101. The study concludes with a Long-Term Extension (LTE) Period lasting 96 weeks, aimed at understanding the long-term impacts of the treatment.

    One of the key aspects being monitored throughout the study, up to Week 145, is the number of participants who experience any treatment-emergent adverse events (TEAEs), which are any new or worsening health issues that occur during the trial.

    This study represents an important step towards finding a new treatment option for those living with Myotonic Dystrophy Type 1, with a strong focus on safety and the overall well-being of the participants.

    FranceGermanyItalyNetherlandsUnited Kingdom
  • Testing setmelanotide for weight loss in genetic obesity

    This study is a research project looking into the effectiveness of a medication called setmelanotide for people who are dealing with obesity due to specific genetic variations. This medication is given under the skin. The study is designed to see if setmelanotide can help people lose weight compared to a placebo, which don’t contain any active medication.

    The study focuses on individuals who have one of several gene variants in the Melanocortin-4 Receptor pathway. These variants include changes in the POMC or PCSK1 genes, the LEPR gene, the SRC1 gene, or the SH2B1 gene. Depending on which gene variant a participant has, they will be placed into one of four sub-studies.

    The main goal of this clinical trial is to measure how much weight participants lose while taking setmelanotide over a period of 52 weeks. This will be compared to the weight loss of participants who receive the placebo. The study is carefully controlled and blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo until the study is completed.

    This trial is an important step in understanding how setmelanotide can help people with obesity linked to specific genetic factors, offering hope for a targeted treatment option.

    FranceGermanyGreeceNetherlandsSpainUnited Kingdom
  • Study of belzutifan for treating advanced cancers

    This clinical trial aim is to test out a new drug called belzutifan, also known as MK-6482 or WELIREG™. It’s a pill patient can take once a day, and the main goal is to see if it can shrink or get rid of tumors in folks with certain types of cancer.

    The cancers the researchers are looking at are pheochromocytoma and paraganglioma, which are tumors that start in the adrenal glands or nervous system. Pancreatic neuroendocrine tumors, tumors related to von Hippel-Lindau disease, advanced gastrointestinal stromal tumors, and other solid tumors with certain genetic changes that involve a protein called HIF-2α, there will be also tested.

    The big thing the researchers are  keeping an eye on is the objective response rate, which means how many folks see their tumors shrink or disappear completely while taking this drug. The researchers will be watching closely for any side effects too, of course, to make sure this new medicine is safe.

    DenmarkFranceGermanyHungaryItalyNetherlandsSpainSwedenUnited Kingdom
  • Testing New Therapies for Glioblastoma Brain Cancer

    Howdy there, partner! This here trial is called the GBM AGILE study, and it’s aiming to find better treatments for a type of brain cancer called glioblastoma. Now, glioblastoma is a real tough customer, but this study is taking a new approach by testing multiple therapies all at once, both for newly diagnosed cases and for those where the cancer has come back.

    The main goal is to find treatments that work better and can be matched to different types of glioblastoma. The study uses a fancy method called Bayesian response adaptive randomization to assign folks to different treatment arms based on how well those treatments are performing. The most important measure they’re looking at is overall survival – how long patients live after starting treatment.

    Some of the therapies being tested include drugs like temozolomide, lomustine, regorafenib, paxalisib, VAL-083, VT1021, and troriluzole. These come in different forms like capsules, tablets, or infusions, and the dosages and schedules vary depending on the drug. The study is set up so that new promising therapies can be added in, and ones that aren’t working so well can be removed as the trial goes on.

    FranceGermany
  • To study the effectiveness of mitotane in preventing cancer recurrence in patients with adrenocortical carcinoma

    The ADIUVO trial is focused on understanding the effectiveness of a treatment called mitotane in patients who have undergone surgery for a rare type of adrenocortical cancer. This cancer has a high chance of coming back after surgery, and previous research suggests that mitotane may help reduce this risk. However, it is important to confirm these results in a study in which patients are randomly assigned to receive mitotane or no additional treatment after surgery. This is particularly important for patients whose cancer is at low or intermediate risk of coming back because doctors need to be sure that the benefits of mitotane outweigh any side effects.

    In this study, the goal is to see if mitotane can help patients live longer without their cancer coming back. Doctors will also assess patients’ overall life expectancy, quality of life and any side effects that may occur as a result of treatment. In addition, they will check whether mitotane levels in the blood influence these results and whether there are differences in results depending on certain characteristics of the cancer.

    Treatment with mitotane will be started at a lower dose and gradually increased depending on your tolerability, with adjustments possible depending on blood levels and side effects. The main goal is to compare how long patients remain cancer-free after surgery, with particular emphasis on their overall well-being and any potential side effects of treatment.

    FranceGermanyItalyNetherlandsUnited Kingdom
  • Comparison of adjuvant therapy for high-risk postoperative adrenocortical carcinoma

    The **ADIUVO-2 Trial** is a phase III clinical study designed to explore the best treatment approach for patients with **Stage I-III Adrenocortical Cancer** that has a high risk of returning after surgery. This trial is comparing two different treatment methods to see which one is more effective in preventing the cancer from coming back.

    One group of patients will receive a medication called **mitotane** by itself, which is known to reduce the amount of cortisol, a substance that can promote the growth of adrenocortical tumor cells. The other group will receive **mitotane** along with two chemotherapy drugs, **cisplatin** and **etoposide**, which work in various ways to stop tumor cells from growing or spreading.

    The main goal of this study is to see which treatment option better prevents the cancer from returning. This is measured by the time patients remain free from cancer recurrence. Additionally, the study will look at the overall survival of patients, how different factors like the level of mitotane in the blood, the stage of the disease, and how well the surgery went might influence the outcomes.

    The trial also aims to understand the impact of starting the treatment early (1-6 weeks after surgery) versus later (more than 6 weeks after surgery) on patient outcomes. Moreover, it will monitor any serious side effects and assess the quality of life of participants throughout the study using a specific questionnaire.

    For those interested in the more scientific aspects, the study will also perform molecular profiling on tumor samples to identify any genetic changes that might be linked to how well patients respond to the treatment or the likelihood of the cancer coming back.

    Participants in the study will be randomly assigned to one of the two treatment groups. Those in the first group will take mitotane daily for up to 2 years unless the cancer progresses or they experience unacceptable side effects. Those in the second group will take mitotane in the same way but will also receive cisplatin and etoposide through an IV for up to 4 cycles, each cycle lasting 21 days, unless the cancer progresses or they experience unacceptable side effects.

    After completing the treatment, patients will be followed up every 6 months to monitor their health and any signs of cancer recurrence.

    FrancePoland
  • Study on the effectiveness of Givinostat in Non-Walking Duchenne Muscular Dystrophy Patients

    This clinical trial is focused on testing the effectiveness, safety, and how well patients can tolerate a medication called Givinostat for those who have Duchenne Muscular Dystrophy (DMD) and can no longer walk. The study is designed for male pediatric patients aged between 9 to less than 18 years. A total of 138 participants will be involved, and they will be divided into two groups. One group will receive Givinostat, and the other group will receive a placebo, which is a substance with no therapeutic effect, designed to mimic Givinostat. This division will be done randomly and both the patients and the doctors will not know who is receiving the actual medication and who is receiving the placebo, making this a double-blind study.

    The main goal of this study is to see if Givinostat can help reduce muscle decline in patients with DMD who cannot walk, by looking at changes in upper limb function after 18 months of treatment. The safety and tolerability of Givinostat in these patients will also be closely monitored.

    Participants will be involved in the study for about 20 to 21 months, which includes a 4-week screening period to confirm eligibility, 18 months of treatment, and a follow-up period. At the end of the treatment period, all participants, regardless of which group they were in, will have the option to join a long-term safety study where they will receive Givinostat.

    BelgiumFranceGermanyItalyNetherlandsUnited Kingdom
  • Clinical Study on Growth and Health in Children with Achondroplasia

    This is a long-term, multi-center, observational study for children aged 2.5 to <17 years who have been diagnosed with achondroplasia. The main objective of the study is to evaluate various aspects of the condition, including growth, medical complications related to achondroplasia, health-related quality of life, body pain, functional abilities, cognitive functions, and treatments received by the participants. The study will monitor changes in height Z score and upper to lower body segment ratio over a period of up to 2 years. No study medication will be administered to the participants during this observational study.

    FranceGermanyItalyNorwaySpainUnited Kingdom
  • CT-EU-00083874

    Study to find the best way to administer pegaspargase in children with acute lymphoblastic leukemia

    This is a study to investigate treatment strategies for children and adolescents diagnosed with acute lymphoblastic leukemia (ALL). The study focuses on evaluating the efficacy of a drug called pegaspargase. The drug works by depriving tumor cells of essential nutrients, contributing to its potential efficacy against ALL in pediatric patients. The study aims to determine the optimal way to administer pegaspargase, comparing a single high dose with two lower doses, with additional doses later in treatment. For those at highest risk, a more intensive treatment plan is being investigated. This includes two larger initial doses, followed by additional doses later in treatment. The study is evaluating factors such as potential serious side effects and overall treatment efficacy.

  • CT-EU-00091315

    Testing infigratinib in children aged 3 to 11 years with achondroplasia

    This study focuses on evaluating the medication Infigratinib in young children aged 3 to 11 diagnosed with Achondroplasia who previously participated in the PROPEL study for at least 6 months. The primary objectives of this study are to assess the safety profile of Infigratinib in this specific age group, evaluate the children’s tolerance to potential side effects, and investigate the therapeutic efficacy of the medication for treating Achondroplasia. During the study, doses of Infigratinib will be incrementally increased to determine the optimal and most effective dosage for the participants.

  • Research to enhance cancer treatments for kids and teens

    This clinical trial, known as CAMPFIRE, encompasses several studies testing new drugs for children and young adults with cancer. It includes various drug combinations such as Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel, Abemaciclib, Irinotecan, and Temozolomide. These trials aim to evaluate the safety and effectiveness of these drugs in treating different cancer types. The study is interventional, with an estimated enrollment of 105 participants, randomized in parallel assignment. The primary purpose is treatment-focused.

    BelgiumFranceGermanyItalyNetherlandsSpainUnited Kingdom
  • Studying rilzabrutinib for chronic immune thrombocytopenia

    The research is underway to evaluate the efficacy and safety of a medication called rilzabrutinib in adults and teenagers with Immune Thrombocytopenia (ITP), a chronic blood condition characterized by a low platelet count. Participants will receive either the medication or a placebo twice daily over a period of about a year and a half. Platelet levels, overall health, and quality of life will be measured before and during the study to gather comprehensive data.

    AustriaFranceGermanyHungaryItalyNetherlandsNorwayPolandSpainUnited Kingdom
  • Continued Parsaclisib treatment for B-cell cancer patients

    This is a phase II clinical trial focused on providing continuation of treatment with a drug called parsaclisib to people diagnosed with B-cell malignancies. The main goal of this study is to expand the treatment regimen established in the previous study. Study participants will receive parsaclisib as a stand-alone therapy (monotherapy) or in combination with other therapeutic agents, which may include itacitinib, ruxolitinib or ibrutinib. The study aims to facilitate participants’ ongoing care and contribute to the broader field of medical research by collecting data on the effectiveness and safety of prolonged use of parsaclisib.

    AustriaBelgiumCzechiaDenmarkFranceHungaryItalyNorwayPolandSpainSwedenUnited Kingdom
  • Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    BelgiumCzechiaFranceGreeceHungaryNetherlandsPolandSpainUnited Kingdom
  • Stomach cancer treatment comparison: trastuzumab deruxtecan vs. ramucirumab & paclitaxel

    This is a thorough comparison study to measure the effectiveness and safety of two treatment paths. It’s designed for individuals who have experienced progression regarding a stomach (gastric) cancer, or cancer of the gastro-esophageal junction (GEJ). The study focuses on those with HER2-positive gastric or GEJ who have previously undergone a trastuzumab-containing regime but have not received further systemic therapy.The research compares the use of trastuzumab deruxtecan, a potent anti-cancer agent, and the combined use of ramucirumab and paclitaxel. The study’s primary goal is to evaluate the overall survival rate, while secondary aims involve examining progression-free survival, response duration, disease control, safety, pharmacokinetics, and immunogenicity.In the study, participants are fairly and randomly assigned to receive one of two treatments. This is crucial in understanding the superiority and safety of these treatment paths, and this knowledge may inform future approaches to treating these types of cancer.

    BelgiumFranceHungaryItalyPolandPortugalRomaniaSpainUnited Kingdom
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    AustriaBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    AustriaFranceGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Exploring the safety of seladelpar in treating primary biliary cholangitis

    This is a long-term study on a drug named seladelpar for people with a liver disease called Primary Biliary Cholangitis (PBC). The main goal is to see if this drug is safe and easy for patients with PBC to use over a long period. A secondary goal is to see if seladelpar can effectively treat PBC and improve the patient’s quality of life. The study will track a few things, like if there are changes in the patient’s liver health which may lead to hospitalization or if the patient’s liver enzymes like alkaline phosphate and bilirubin level normalize or not after taking this drug.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Study on combining encorafenib and cetuximab for local colon or upper rectum cancer

    This research study is exploring the use of two medications, encorafenib and cetuximab, in individuals diagnosed with a particular form of colorectal or upper rectal cancer before their surgical procedures. The focus is on patients whose cancer carries the BRAF V600E genetic alteration (is a genetic change in cancer cells that makes them grow faster than normal cells—its presence is associated with a worse prognosis). The aim is to enroll approximately 30 individuals with this genetic change in their cancer cells. If a patient’s cancer lacks the BRAF V600E alteration or has a different alteration that doesn’t meet the study criteria, they will not participate. The objective of this research study is to assess the effectiveness of these medications for this group of patients.
    France

See more clinical trials in other cities in France:

.